Antibodies
The present invention relates to an anti-CSF-1R antibody and binding fragments thereof, DNA encoding the same, host cells comprising said DNA and methods of expressing the antibody or binding fragment in a host cell. The present invention also extends to pharmaceutical compositions comprising the antibody or a binding fragment thereof and use of the antibody, binding fragment and compositions comprising the same in treatment.
1. A method for the treatment of a cancer comprising administering an anti-colony stimulating factor 1 receptor (CSF-1R) antibody comprising a heavy chain variable domain, said heavy chain variable domain comprising SEQ ID NO: 4 (CDR-H1), SEQ ID NO: 5 (CDR-H2) and SEQ ID NO: 6 (CDR-H3) and a light chain variable domain comprising SEQ ID NO: 1 (CDR-L1), SEQ ID NO: 2 (CDR-L2) and SEQ ID NO: 3 (CDR-L3) or a pharmaceutical composition comprising said antibody.
2. The method according to claim 1 , wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, bone cancer, colorectal cancer, leukaemia, lymphoma, skin cancer, esophageal cancer, gastric cancer, astrocytic cancer, endometrial cancer, cervical cancer, bladder cancer, renal cancer, lung cancer, liver cancer, thyroid cancer, head and neck cancer, pancreatic cancer and ovarian cancer.
3. The method according to claim 1 , wherein the heavy chain comprises SEQ ID NO:23.
4. The method according to claim 1 , wherein the light chain comprises SEQ ID NO:15.
5. The method according to claim 1 , wherein said anti-colony stimulating factor 1 receptor (CSF-1R) antibody comprises a complete antibody molecule having full length heavy and light chains or is an antigen binding fragment thereof.
6. The method according to claim 1 , wherein said anti-colony stimulating factor 1 receptor (CSF-1R) antibody comprises a heavy chain comprising SEQ ID NO:23 and a light chain comprising SEQ ID NO:15.
7. The method according to claim 1 , wherein said anti-colony stimulating factor 1 receptor (CSF-1R) antibody comprises a heavy chain comprising SEQ ID NO:27 and a light chain comprising SEQ ID NO:19.